Table 5.6a

Immunosuppression Use for Induction, 1995 to 2004

Recipients with Kidney Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 11,078 11,398 11,701 12,446 12,756 13,611 14,263 14,777 15,134 16,000
With Immunosuppression Info 10,833 11,158 11,607 12,332 12,482 13,244 14,106 14,598 14,933 15,550
Induction Drugs 20.3% 2.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 1.4% 15.3% 17.3% 12.2% 6.6% 3.2% 2.5% 1.9% 1.1% 1.8%
OKT3 25.1% 21.4% 17.7% 10.0% 3.9% 1.8% 0.8% 0.9% 0.4% 0.3%
Thymoglobulin 0.0% 0.0% 0.0% 0.2% 4.9% 10.1% 17.0% 25.7% 33.6% 36.6%
Zenapax 0.1% 0.2% 0.2% 13.0% 16.5% 13.1% 14.4% 12.9% 12.5% 11.2%
Simulect 0.2% 0.6% 0.1% 5.0% 17.2% 26.5% 25.2% 26.3% 21.6% 18.9%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3.6% 6.8%
No Induction Drugs Recorded 54.1% 61.5% 65.7% 61.1% 53.0% 47.8% 42.6% 35.3% 30.2% 28.1%


Source: OPTN/SRTR Data as of May 2, 2005.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.